Disease Detail

ID DOID:3620
Name central nervous system cancer
Definition A nervous system cancer that is located_in the central nervous system.
Source DiseaseOntology.org
Alt Ids DOID:0060093 DOID:1318
Path disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
NRAS mutant Trametinib central nervous system cancer sensitive detail...
Unknown unknown CC-122 central nervous system cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00939770 Phase Ib/II Crizotinib Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed
NCT02255461 Phase I Palbociclib Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Terminated
NCT02303028 Phase Ib/II Pazopanib + Topotecan Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours Unknown status
NCT02390752 Phase Ib/II Pexidartinib PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Recruiting
NCT02564198 Phase I Ramucirumab A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Recruiting
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Recruiting
NCT02637687 Phase I Larotrectinib A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT) Recruiting
NCT02650401 Phase I Entrectinib Study Of Entrectinib (Rxdx-101) in Children and Adolescents With No Curative First-Line Treatment Option, Recurrent or Refractory Solid Tumors And Primary Cns Tumors, With or Without Trk, Ros1, or Alk Fusions Recruiting
NCT02653196 Phase II Thiotepa Etoposide Alemtuzumab Palifermin Fludarabine + Melphalan Cyclosporine + Mycophenolate mofetil + Tacrolimus A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors Terminated
NCT02677116 Phase I Doxorubicin Ifosfamide Irinotecan + Vincristine Olaratumab A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer Completed
NCT02780804 Phase I Entinostat Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Active, not recruiting
NCT02793466 Phase I Durvalumab Durvalumab in Pediatric and Adolescent Patients Recruiting
NCT02808650 Phase I Prexasertib Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Recruiting
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting
NCT02932280 Phase Ib/II Neratinib Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment Recruiting
NCT03050450 Phase I Lenalidomide + Vorinostat Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors Suspended
NCT03130959 Phase II Ipilimumab + Nivolumab Nivolumab An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) Active, not recruiting
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting
NCT03323034 Phase I Irinotecan + MLN4924 + Temozolomide Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma Recruiting
NCT03371004 Phase I DM-CHOC-PEN DM-CHOC-PEN Plus Radiation for Brain Tumors Recruiting
NCT03389802 Phase I APX005M Phase I Study of APX005M in Pediatric CNS Tumors Recruiting
NCT03429803 Phase Ib/II MLN2480 TAK-580 In Gliomas and Other Tumors Recruiting
NCT03434262 Phase I Filgrastim + Gemcitabine + Pegfilgrastim + Ribociclib Trametinib Sonidegib Ribociclib Ribociclib + Trametinib Ribociclib + Sonidegib Molecularly-Driven Doublet Therapy for Recurrent CNS Malignant Neoplasms Recruiting
NCT03500991 Phase I HER2 CAR-T cells HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors Recruiting
NCT03554707 Phase I Bevacizumab + Irinotecan + SGT-53 + Temozolomide SGT-53 in Children With Recurrent or Progressive CNS Malignancies Not yet recruiting
NCT03598244 Phase I Savolitinib Volitinib in Treating Participants With Recurrent or Refractory Primary CNS Tumors Recruiting
NCT03638167 Phase I EGFR806-specific CAR T cells EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors Recruiting
NCT03690869 Phase Ib/II Cemiplimab REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Recruiting
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03899792 Phase Ib/II LOXO-292 A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors (LIBRETTO-121) Recruiting